tiprankstipranks
Advertisement
Advertisement

BOVNF Stock Latest News

BioInvent’s BI-1808 Plus Keytruda Shows Strong Ovarian Cancer Signal in Phase 2a
Company AnnouncementsBioInvent’s BI-1808 Plus Keytruda Shows Strong Ovarian Cancer Signal in Phase 2a
4d ago
BioInvent Showcases Promising Ovarian Cancer Antibody BI-1808 in Virtual KOL Event
PremiumCompany Announcements
BioInvent Showcases Promising Ovarian Cancer Antibody BI-1808 in Virtual KOL Event
5d ago
BioInvent to Showcase Promising BI-1206 Triplet Data in Relapsed NHL at EHA 2026
PremiumCompany Announcements
BioInvent to Showcase Promising BI-1206 Triplet Data in Relapsed NHL at EHA 2026
13d ago
BioInvent’s BI-1808 Delivers Promising CTCL Responses in Phase 2a Trial
PremiumCompany Announcements
BioInvent’s BI-1808 Delivers Promising CTCL Responses in Phase 2a Trial
13d ago
BioInvent AGM Backs New Incentive Plan, Share Issue Mandate and Board Changes
PremiumCompany Announcements
BioInvent AGM Backs New Incentive Plan, Share Issue Mandate and Board Changes
26d ago
BioInvent Ramps Up Oncology Profile With Dual KOL Events Around ASCO and EHA
PremiumCompany AnnouncementsBioInvent Ramps Up Oncology Profile With Dual KOL Events Around ASCO and EHA
26d ago
BioInvent Narrows Focus on Immuno-Oncology as Q1 Loss Widens and Key Trials Advance
Premium
Company Announcements
BioInvent Narrows Focus on Immuno-Oncology as Q1 Loss Widens and Key Trials Advance
26d ago
BioInvent to showcase promising BI-1808 and KEYTRUDA combo data in recurrent ovarian cancer at ASCO 2026
Premium
Company Announcements
BioInvent to showcase promising BI-1808 and KEYTRUDA combo data in recurrent ovarian cancer at ASCO 2026
1M ago
BioInvent Narrows Pipeline and Advances Lead Cancer Antibodies in Strategically Focused 2025
PremiumCompany Announcements
BioInvent Narrows Pipeline and Advances Lead Cancer Antibodies in Strategically Focused 2025
2M ago
BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3
PremiumCompany Announcements
BioInvent Secures €1 Million Milestone as Endometriosis Antibody Enters Phase 3
2M ago
BioInvent Calls 2026 AGM, Sets Governance and Voting Framework
PremiumCompany Announcements
BioInvent Calls 2026 AGM, Sets Governance and Voting Framework
2M ago
BioInvent Earnings Call: Strong Data, Tight Runway
PremiumCompany Announcements
BioInvent Earnings Call: Strong Data, Tight Runway
3M ago
BioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
PremiumCompany AnnouncementsBioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
3M ago
BioInvent to Present 2025 Year-End Results in Investor Webcast
Premium
Company Announcements
BioInvent to Present 2025 Year-End Results in Investor Webcast
3M ago
BioInvent Taps Industry Heavyweights for Board as Cancer Pipeline Advances
Premium
Company Announcements
BioInvent Taps Industry Heavyweights for Board as Cancer Pipeline Advances
3M ago
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
PremiumCompany Announcements
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
5M ago
BioInvent Steps Up Investor Outreach with Series of 2026 Healthcare Conferences
PremiumCompany Announcements
BioInvent Steps Up Investor Outreach with Series of 2026 Healthcare Conferences
5M ago
BioInvent’s BT-001 Clinical Trial Termination: Implications for Investors
PremiumCompany Announcements
BioInvent’s BT-001 Clinical Trial Termination: Implications for Investors
5M ago
BOVNF
BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
PremiumCompany Announcements
BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
6M ago
BioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
PremiumCompany AnnouncementsBioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
6M ago
BioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment
Premium
Company Announcements
BioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment
6M ago
BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation
Premium
Company Announcements
BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >